MedTrace Logo

Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid

NCT00692705 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2009-01-23

No results posted yet for this study

Summary

The study is carried out in order to investigate if \[11C\]AZD2995, compared to \[11C\]AZD2184, is a more suitable PET ligand for in vivo imaging of β amyloid depositions in the human brain. In the study the two PET ligands will be examined in both healthy volunteers and patients with Alzheimer's Disease.

Conditions

  • Alzheimer´s Disease

Interventions

DRUG

Radioligand (11C)AZD2995

Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers.

DRUG

Radioligand (11C)AZD2184

Single dose of i.v solution. Once for AD patients respective healthy volunteers.

Sponsors & Collaborators

Principal Investigators

  • Maria E Jönhagen · Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden

  • Ingemar Bylesjö · AstraZeneca Clinical Pharmacology Unit, Stockholm, Sweden

  • Emma Gyllenpalm · AstraZeneca R&D, Södertälje, Sweden

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00692705 on ClinicalTrials.gov